Aptose Biosciences (NASDAQ:APTO) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note issued on Thursday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $2.00 target price on shares of Aptose Biosciences in a report on Friday, January 10th.

Aptose Biosciences Price Performance

NASDAQ APTO opened at $0.21 on Thursday. The stock’s 50 day simple moving average is $0.24 and its 200 day simple moving average is $0.39. Aptose Biosciences has a one year low of $0.13 and a one year high of $2.42. The firm has a market cap of $12.40 million, a PE ratio of -0.07 and a beta of 0.87.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC purchased a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences as of its most recent SEC filing. 26.62% of the stock is owned by hedge funds and other institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.